Sign in

    Jacqueline Kisa

    Research Analyst at TD Cowen

    Jacqueline Kisa is an Equity Research Associate at TD Cowen, specializing in life sciences with a focus on tools, diagnostics, and biotechnology companies such as AbCellera Biologics and OmniAb Inc. She is actively involved in research coverage, contributing analytical insights and facilitating Q&A on earnings calls for leading biopharma firms, though publicly available performance track records and rankings are currently limited. Kisa began her equity research career at TD Securities (USA) LLC before joining TD Cowen, building expertise in sector coverage across both firms. She holds pertinent industry credentials including FINRA registration and securities licenses acquired during her tenure in research analysis roles.

    Jacqueline Kisa's questions to OABI leadership

    Jacqueline Kisa's questions to OABI leadership • Q2 2025

    Question

    Jacqueline Kisa of TD Cowen questioned the process for existing partners to adopt the Exploration platform and inquired about the nature of the next technology launch planned for 2025.

    Answer

    CEO Matthew Foehr explained that partners can continue to access Exploration's capabilities through OmniAb's services, but now also have the option to purchase an instrument for in-house use. CFO Kurt Gustafson added that non-partners must first sign a license to access the technology. Regarding the next launch, Mr. Foehr confirmed it would happen this year and be highly relevant to efficient antibody discovery, but declined to provide further details.

    Ask Fintool Equity Research AI

    Jacqueline Kisa's questions to AbCellera Biologics (ABCL) leadership

    Jacqueline Kisa's questions to AbCellera Biologics (ABCL) leadership • Q4 2024

    Question

    Jacqueline Kisa from TD Securities asked about potential exposure to Canadian retaliatory tariffs on U.S. goods. She also inquired about AbCellera's strategy for advancing its internal assets toward commercialization versus partnering or selling them.

    Answer

    CFO Andrew Booth clarified that Canadian government guidance includes exemptions for bio-manufacturing products, so they expect no material impact from tariffs. CEO Carl L. Hansen addressed the pipeline strategy, stating that they evaluate each program to optimize returns. He noted that while they are prepared to take some programs to commercialization, partnering is a likely scenario for others, such as ABCL575, to maximize value across multiple indications with a large partner.

    Ask Fintool Equity Research AI

    Jacqueline Kisa's questions to Ginkgo Bioworks Holdings (DNA) leadership

    Jacqueline Kisa's questions to Ginkgo Bioworks Holdings (DNA) leadership • Q3 2024

    Question

    Jacqueline Kisa asked about the next steps for Ginkgo's AI capabilities, specifically whether the focus is on data generation or building a full software platform. She also inquired about the Q4 OpEx outlook and the pace of cost savings.

    Answer

    CEO Jason Kelly explained that AI is a major change driver in biopharma and Ginkgo's strategy is to launch models via API to engage the scientific community, complemented by its data points business. He noted the company remains open-minded on the long-term direction. CFO Mark Dmytruk stated that while cost reductions will continue in Q4, the magnitude of the quarter-over-quarter drop seen from Q2 to Q3 would not be repeated.

    Ask Fintool Equity Research AI